Summarized by Masters of Longevity from PR Newswire.
New clinical, biomarker, and preclinical data are presented showing continued disability trends, EBV-related immune changes, and neuroprotective signals for a Nurr1-activating oral MS candidate.
Key Takeaways
- CALLIPER open-label extension showed maintained favorable disability trends with only 6.5% discontinuation through the January 27, 2026 cutoff.
- Vidofludimus calcium significantly reduced EBV-specific TCRβ sequence matches versus placebo (−0.65 matches; p=0.0004) while influenza A matches were unchanged.
- Preclinical models showed vidofludimus calcium promoted neuronal survival under apoptotic stress and reduced microglia-driven neuronal loss, effects requiring Nurr1.
